Table 9.
Predicting Factors for OS of DEB-TACE Treatment in Patients With HCC.a
| Univariate Cox Regression | Multivariate Cox Regression | |||||||
|---|---|---|---|---|---|---|---|---|
| 95% CI | 95% CI | |||||||
| P Value | HR | Lower | Higher | P Value | HR | Lower | Higher | |
| Age ≥60 years | .199 | 0.246 | 0.029 | 2.090 | - | - | - | - |
| Gender (Female) | .815 | 0.776 | 0.092 | 6.506 | - | - | - | - |
| HBV | .251 | 0.244 | 0.022 | 2.711 | - | - | - | - |
| Drink | .844 | 0.847 | 0.163 | 4.417 | - | - | - | - |
| Cirrhosis | .381 | 0.511 | 0.114 | 2.295 | - | - | - | - |
| Multifocal vs unifocal | .451 | 2.304 | 0.264 | 20.145 | - | - | - | - |
| Largest nodule size ≥5.7 cm | .306 | 2.364 | 0.455 | 12.273 | - | - | - | - |
| Bilobar vs unilobar | .301 | 2.226 | 0.489 | 10.141 | - | - | - | - |
| Portal vein invasion | .060 | 4.837 | 0.933 | 25.066 | .146 | 10.606 | 0.440 | 255.690 |
| Hepatic vein invasion | .601 | 0.566 | 0.067 | 4.777 | - | - | - | - |
| Higher ECOG | .046 | 4.752 | 1.026 | 22.018 | .327 | 2.730 | 0.367 | 20.314 |
| Higher child-pugh stage | .003 | 12.219 | 2.334 | 63.984 | .159 | 13.138 | 0.364 | 474.736 |
| Higher BCLC stage | .045 | 2.518 | 1.020 | 6.215 | .678 | 0.735 | 0.172 | 3.136 |
| WBC >4.80, ×109 cell/L | .259 | 2.584 | 0.496 | 13.449 | - | - | - | - |
| RBC >4.01, (×1012 cell/L | .474 | 0.560 | 0.115 | 2.736 | - | - | - | - |
| ANC% >64.10 | .139 | 3.463 | 0.667 | 17.988 | - | - | - | - |
| HB >12.70, g/L | .529 | 0.615 | 0.135 | 2.796 | - | - | - | - |
| PLT >97.00, ×109 cell/L | .821 | 1.189 | 0.265 | 5.331 | - | - | - | - |
| ALB >37.20, g/L | .049 | 0.117 | 0.014 | 0.994 | .042 | 0.004 | 0.000 | 0.822 |
| TP >66.70, g/L | .511 | 0.602 | 0.133 | 2.727 | - | - | - | - |
| TBIL >17.10, μmol/L | .202 | 55.574 | 0.117 | - | - | - | - | - |
| TBA >14.35, I/L | .146 | 0.295 | 0.057 | 1.527 | - | - | - | - |
| ALT >31.00, μ/L | .416 | 0.531 | 0.115 | 2.443 | - | - | - | - |
| AST >40.00, μ/L | .165 | 3.283 | 0.614 | 17.565 | - | - | - | - |
| ALP >147.00, μ/L | .370 | 1.987 | 0.443 | 8.920 | - | - | - | - |
| BCr >66.00, μmol/L | .476 | 0.542 | 0.101 | 2.913 | - | - | - | - |
| BUN >3.92, mmol/L | .017 | 0.070 | 0.008 | 0.617 | .047 | 0.015 | 0.000 | 0.945 |
| AFP >18.46, μg/L | .579 | 0.652 | 0.144 | 2.954 | - | - | - | - |
| CEA >2.74, μg/L | .803 | 0.826 | 0.183 | 3.174 | - | - | - | - |
| CA199 >24.80, kU/L | .180 | 3.083 | 0.595 | 15.986 | - | - | - | - |
| Previous cTACE | .683 | 0.725 | 0.154 | 3.407 | - | - | - | - |
| Previous surgery | .492 | 1.790 | 0.340 | 9.424 | - | - | - | - |
| Previous systematic chemotherapy | .207 | 4.099 | 0.458 | 36.729 | - | - | - | - |
| Previous radiofrequency ablation | .824 | 1.271 | 0.153 | 10.570 | - | - | - | - |
| Previous targeted therapy | .846 | 0.048 | - | - | - | - | - | - |
| Adriamycin drug (chemoembolization reagents) | .416 | 32.493 | - | - | - | - | - | - |
| Irinotecan (chemoembolization reagents) | .416 | 0.031 | - | - | - | - | - | - |
| Combination of ordinary embolization agent | .279 | 2.479 | 0.480 | 12.806 | - | - | - | - |
Abbreviations: ALT, alanine aminotransferase; ALB, albumin; ALP, alkaline phosphatase; ANC, absolute neutrophil count; AFP, alpha fetoprotein; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; BUN, blood urea nitrogen; CA199, carbohydrate antigen199; cTACE, conventional transarterial chemo-embolization; CEA, carcino-embryonic antigen; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; HBV, hepatic b virus; HB, hemoglobin; PLT, platelet; RBC, red blood cell; TP, total protein; TBIL, total bilirubin; TBA, total bile acid; WBC, while blood cell.
aData were presented as P value, HR (hazard ratio), and 95% CI. Significance was determined by univariate and multivariate Cox regression analysis. All factors with P value < .1 in univariate model were further analyzed by multivariate model. P value < .05 was considered significant.